Skip to content
Homepage
Author:
NUCLIDIUM AG
Posted Date:
May 27, 2026
NUCLIDIUM Announces Closing of Series B Extension Bringing Total Round to CHF 105 Million
NUCLIDIUM AG
May 27, 2026
NUCLIDIUM Announces Issuance of New U.S. Patent Covering its 61Cu-based Radiodiagnostic Program for PSMA-positive Prostate Cancer
NUCLIDIUM AG
January 28, 2026
